GlassScriptPhysician profile
Susan E Evans
NPI 1376143446
$10,430.01
in general payments reported to CMS, 2019-2025
58 companies · $1,745 in 2025
The $1,745 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,002 · 2022: $2,501 · 2023: $2,310 · 2024: $1,872 · 2025: $1,745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,927.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,197.56 | 2021-2025 | |
| Amgen INC. | $843.86 | 2021-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $779.20 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $652.35 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $611.12 | 2021-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $587.33 | 2021-2025 | Rexulti, Abilify Maintena |
| Astrazeneca Pharmaceuticals LP | $528.43 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $483.77 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $438.16 | 2021-2024 | |
| Glaxosmithkline, LLC. | $401.59 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Corcept Therapeutics | $312.42 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $261.96 | 2021-2024 | |
| Corium, LLC | $228.94 | 2023 | Azstarys |
| Insulet Corporation | $208.10 | 2023-2025 | Omnipod |
| Boehringer Ingelheim Pharmaceuticals, INC. | $205.42 | 2021-2025 | Jardiance, Tradjenta |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $201.91 | 2022 | |
| Antares Pharma, INC. | $187.33 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Astellas Pharma US INC | $186.16 | 2022-2025 | Veozah, Myrbetriq |
| Janssen Pharmaceuticals, INC | $140.12 | 2022-2025 | Xarelto, Spravato |
| Sanofi-Aventis U.S. LLC | $123.06 | 2022-2023 | |
| Amarin Pharma, INC. | $109.76 | 2021 | |
| Merck Sharp & Dohme LLC | $96.49 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Lundbeck LLC | $95.85 | 2022-2025 | Rexulti |
| Ironwood Pharmaceuticals, INC | $93.58 | 2021-2023 | Linzess |
| Collegium Pharmaceutical, INC. | $90.98 | 2024-2025 | Belbuca |
| Dexcom, INC. | $89.98 | 2021-2024 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $82.66 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $79.45 | 2022-2025 | Caplyta |
| Sumitomo Pharma America, INC. | $79.41 | 2023-2025 | Gemtesa |
| Vanda Pharmaceuticals INC. | $77.85 | 2023-2025 | Fanapt, Hetlioz |
| Paratek Pharmaceuticals, INC. | $64.63 | 2021-2022 | |
| Kowa Pharmaceuticals America, INC. | $64.56 | 2022-2024 | Zoryve |
| Indivior INC. | $62.29 | 2024-2025 | Sublocade |
| Xeris Pharmaceuticals, INC. | $58.97 | 2022-2023 | Gvoke Hypopen, Keveyis |
| Idorsia Pharmaceuticals US INC | $55.07 | 2022-2023 | Quviviq |
| Braeburn INC. | $54.04 | 2025 | Brixadi |
| Exact Sciences Corporation | $49.72 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $48.45 | 2021 | |
| Nestle Healthcare Nutrition INC. | $42.88 | 2021-2022 | |
| Ardelyx, INC. | $41.99 | 2024-2025 | Ibsrela |
| Eisai INC. | $40.65 | 2021-2022 | |
| Tolmar, INC. | $36.14 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.11 | 2021-2022 | |
| Stryker Corporation | $33.13 | 2024 | Surgicount |
| Phathom Pharmaceuticals, INC. | $31.26 | 2024 | Voquezna |
| Halozyme INC | $30.56 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $24.41 | 2023 | Austedo |
| Mannkind Corporation | $22.89 | 2024 | |
| Ucb, INC. | $21.67 | 2023 | Nayzilam |
| Supernus Pharmaceuticals, INC. | $20.56 | 2022 | Xyosted, Tlando |
| Alkermes, INC. | $17.90 | 2025 | Vivitrol |
| Clarus Therapeutics INC. | $16.94 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.59 | 2021 | |
| Impel Pharmaceuticals INC. | $13.80 | 2023 | Trudhesa |
| Horizon Therapeutics Plc | $13.52 | 2021 | |
| Scilex Pharmaceuticals INC. | $13.36 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.26 | 2022 | |
| Medtronic, INC. | $11.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.